Patent: 10,308,715
✉ Email this page to a colleague
Summary for Patent: 10,308,715
Title: | Antibody targeting osteoclast-related protein Siglec-15 |
Abstract: | To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like. |
Inventor(s): | Hiruma; Yoshiharu (Tokyo, JP), Tsuda; Eisuke (Tokyo, JP) |
Assignee: | DAIICHI SANKYO COMPANY, LIMITED (Tokyo, JP) |
Application Number: | 15/729,947 |
Patent Claims: | see list of patent claims |
Details for Patent 10,308,715
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Nps Pharmaceuticals, Inc. | NATPARA | parathyroid hormone | For Injection | 125511 | 01/23/2015 | ⤷ Try a Trial | 2027-10-11 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |